Oksana Zavidij

1.5k total citations
21 papers, 630 citations indexed

About

Oksana Zavidij is a scholar working on Molecular Biology, Hematology and Oncology. According to data from OpenAlex, Oksana Zavidij has authored 21 papers receiving a total of 630 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Molecular Biology, 10 papers in Hematology and 5 papers in Oncology. Recurrent topics in Oksana Zavidij's work include Multiple Myeloma Research and Treatments (7 papers), Virus-based gene therapy research (5 papers) and RNA Interference and Gene Delivery (3 papers). Oksana Zavidij is often cited by papers focused on Multiple Myeloma Research and Treatments (7 papers), Virus-based gene therapy research (5 papers) and RNA Interference and Gene Delivery (3 papers). Oksana Zavidij collaborates with scholars based in United States, Germany and Italy. Oksana Zavidij's co-authors include Hanno Glimm, Manfred Schmidt, Christof von Kalle, Claudia R. Ball, Ali Nowrouzi, Sebastian M. Dieter, Friederike Herbst, Ulrich Abel, Anne I.J. Arens and Wilko Weichert and has published in prestigious journals such as Nature Communications, Nano Letters and Blood.

In The Last Decade

Oksana Zavidij

21 papers receiving 623 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Oksana Zavidij United States	9	302	284	132	132	84	21	630
Tobias G. Kapp Germany	18	553 1.8×	217 0.8×	87 0.7×	158 1.2×	55 0.7×	26	1.2k
Bingyan Wu United States	10	346 1.1×	407 1.4×	81 0.6×	131 1.0×	85 1.0×	26	982
Alexander Zheleznyak United States	16	352 1.2×	298 1.0×	66 0.5×	100 0.8×	70 0.8×	26	945
Dimitri Livitz United States	12	361 1.2×	129 0.5×	316 2.4×	52 0.4×	64 0.8×	20	806
Michael Timaner Israel	14	301 1.0×	359 1.3×	170 1.3×	101 0.8×	37 0.4×	20	758
Claudia Gottstein Germany	16	354 1.2×	150 0.5×	82 0.6×	149 1.1×	108 1.3×	27	856
Aurélie Dutour France	13	310 1.0×	282 1.0×	190 1.4×	142 1.1×	31 0.4×	35	829
Christoph Muus United States	7	692 2.3×	109 0.4×	230 1.7×	185 1.4×	83 1.0×	9	949
Klemens Löster Germany	18	425 1.4×	193 0.7×	116 0.9×	110 0.8×	110 1.3×	39	918

Countries citing papers authored by Oksana Zavidij

Since Specialization

Citations

This map shows the geographic impact of Oksana Zavidij's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Oksana Zavidij with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Oksana Zavidij more than expected).

Fields of papers citing papers by Oksana Zavidij

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Oksana Zavidij. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Oksana Zavidij. The network helps show where Oksana Zavidij may publish in the future.

Co-authorship network of co-authors of Oksana Zavidij

This figure shows the co-authorship network connecting the top 25 collaborators of Oksana Zavidij. A scholar is included among the top collaborators of Oksana Zavidij based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Oksana Zavidij. Oksana Zavidij is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Haines, Eric, Michael Burke, Víctor R. De Jesús, et al.. (2023). Abstract PR10: IK-595, a MEK-RAF complex inhibitor, obviates CRAF mediated resistance resulting in superior RAS/MAPK pathway inhibition and anti-tumor activity in RAS/RAF altered cancers. Molecular Cancer Research. 21(5_Supplement). PR10–PR10. 1 indexed citations

Haradhvala, Nicholas J., Jean-Baptiste Alberge, Romanos Sklavenitis‐Pistofidis, et al.. (2022). Single cell characterization of myeloma and its precursor conditions reveals transcriptional signatures of early tumorigenesis. Nature Communications. 13(1). 7040–7040. 31 indexed citations

Scandura, Joseph M., Srđan Verstovšek, Marina Kremyanskaya, et al.. (2022). Clinical Benefit Associated with Biomarker Changes Indicative of Disease Modification in Patients with Myelofibrosis Treated with the BET Inhibitor Pelabresib As Monotherapy or in Combination with Ruxolitinib. Blood. 140(Supplement 1). 1523–1525. 2 indexed citations

Zavidij, Oksana, Nicholas J. Haradhvala, Rosana Meyer, et al.. (2022). MPN-238 Single-Cell RNA Profiling of Myelofibrosis Patients Reveals Pelabresib-Induced Decrease of Megakaryocytic Progenitors and Normalization of CD4+ T Cells in Peripheral Blood. Clinical Lymphoma Myeloma & Leukemia. 22. S331–S332. 2 indexed citations

Zavidij, Oksana, Rosana Meyer, J Cui, et al.. (2022). S192: SINGLE-CELL RNA PROFILING OF MYELOFIBROSIS PATIENTS REVEALS PELABRESIB-INDUCED DECREASE OF MEGAKARYOCYTIC PROGENITORS AND NORMALIZATION OF CD4+ T CELLS IN PERIPHERAL BLOOD. HemaSphere. 6. 93–94. 1 indexed citations

Herbst, Friederike, Peer Wünsche, Alexander Arthur Wurm, et al.. (2021). The balance between the intronic miR-342 and its host gene Evl determines hematopoietic cell fate decision. Leukemia. 35(10). 2948–2963. 11 indexed citations

Haradhvala, Nicholas J., Romanos Sklavenitis‐Pistofidis, Tarek H. Mouhieddine, et al.. (2021). Single Cell Characterization of Myeloma and Its Precursor Conditions Reveals Transcriptional Signatures of Early Tumorigenesis. Blood. 138(Supplement 1). 2219–2219. 6 indexed citations

Ghobrial, Irene M., Chia‐Jen Liu, Robert Redd, et al.. (2019). A Phase Ib/II Trial of the First-in-Class Anti-CXCR4 Antibody Ulocuplumab in Combination with Lenalidomide or Bortezomib Plus Dexamethasone in Relapsed Multiple Myeloma. Clinical Cancer Research. 26(2). 344–353. 79 indexed citations

Sklavenitis‐Pistofidis, Romanos, Mairéad Reidy, Daisy Huynh, et al.. (2019). Founding precision therapy for 1q-amplified multiple myeloma. Clinical Lymphoma Myeloma & Leukemia. 19(10). e50–e50. 2 indexed citations

10.

Tsukamoto, Shokichi, Marianne Bengtson Løvendorf, Jihye Park, et al.. (2018). Inhibition of microRNA-138 enhances bone formation in multiple myeloma bone marrow niche. Leukemia. 32(8). 1739–1750. 33 indexed citations

11.

Detappe, Alexandre, Hung V.‐T. Nguyen, C. Mathieu, et al.. (2018). A Rationally Designed Novel Polymer for Safe and Synergistic Delivery of High Dose Bortezomib, Pomalidomide/Lenalidomide, and Dexamethasone for Multiple Myeloma. Blood. 132(Supplement 1). 4681–4681. 1 indexed citations

12.

Detappe, Alexandre, Eloïse Thomas, Mark W. Tibbitt, et al.. (2017). Ultrasmall Silica-Based Bismuth Gadolinium Nanoparticles for Dual Magnetic Resonance–Computed Tomography Image Guided Radiation Therapy. Nano Letters. 17(3). 1733–1740. 111 indexed citations

13.

Detappe, Alexandre, Eloïse Thomas, Mark W. Tibbitt, et al.. (2017). Silica-Based Bismuth-Gadolinium Nanoparticles for MRI and CT Image-Guided Radiation Therapy. International Journal of Radiation Oncology*Biology*Physics. 99(2). S198–S198. 1 indexed citations

14.

Sacco, Antonio, Yawara Kawano, Michele Moschetta, et al.. (2017). A novel in vivo model for studying conditional dual loss of BLIMP‐1 and p53 in B‐cells, leading to tumor transformation. American Journal of Hematology. 92(8). E138–E145. 4 indexed citations

15.

Zavidij, Oksana, Claudia R. Ball, Friederike Herbst, et al.. (2012). Stable Long-Term Blood Formation by Stem Cells in Murine Steady-State Hematopoiesis. Stem Cells. 30(9). 1961–1970. 9 indexed citations

16.

Ball, Claudia R., Francesca Tuorto, Ali Nowrouzi, et al.. (2012). Extensive Methylation of Promoter Sequences Silences Lentiviral Transgene Expression During Stem Cell Differentiation In Vivo. Molecular Therapy. 20(5). 1014–1021. 78 indexed citations

17.

Dieter, Sebastian M., Claudia R. Ball, Christopher M. Hoffmann, et al.. (2011). Distinct Types of Tumor-Initiating Cells Form Human Colon Cancer Tumors and Metastases. Cell stem cell. 9(4). 357–365. 225 indexed citations

18.

Herbst, Friederike, Claudia R. Ball, Oksana Zavidij, et al.. (2010). 10-Year stability of clinical-grade serum-free γ-retroviral vector-containing medium. Gene Therapy. 18(2). 210–212. 3 indexed citations

19.

Zavidij, Oksana, Claudia R. Ball, Friederike Herbst, et al.. (2010). Hematopoietic activity of human short-term repopulating cells in mobilized peripheral blood cell transplants is restricted to the first 5 months after transplantation. Blood. 115(24). 5023–5025. 2 indexed citations

20.

Knopf, Charles W., Oksana Zavidij, Ingeborg Režuchová, & J Rajcáni. (2008). Evaluation of the T-REx™ transcription switch for conditional expression and regulation of HSV-1 vectors. Virus Genes. 36(1). 55–66. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact